Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

snoRNA and piRNA expression levels modified by tobacco use in women with lung adenocarcinoma.

Nogueira Jorge NA, Wajnberg G, Ferreira CG, de Sa Carvalho B, Passetti F.

PLoS One. 2017 Aug 17;12(8):e0183410. doi: 10.1371/journal.pone.0183410. eCollection 2017.

2.

Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.

Liu T, Krysiak K, Shirai CL, Kim S, Shao J, Ndonwi M, Walter MJ.

PLoS One. 2017 Feb 8;12(2):e0170470. doi: 10.1371/journal.pone.0170470. eCollection 2017.

3.

The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.

Sperling AS, Gibson CJ, Ebert BL.

Nat Rev Cancer. 2017 Jan;17(1):5-19. doi: 10.1038/nrc.2016.112. Epub 2016 Nov 11. Review.

4.

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.

Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ.

Clin Cancer Res. 2016 Dec 1;22(23):5783-5794. Epub 2016 May 27.

5.

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL.

Nature. 2015 Jul 9;523(7559):183-188. doi: 10.1038/nature14610. Epub 2015 Jul 1.

6.

Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells.

Krysiak K, Tibbitts JF, Shao J, Liu T, Ndonwi M, Walter MJ.

Exp Hematol. 2015 Apr;43(4):319-30.e10. doi: 10.1016/j.exphem.2014.12.005. Epub 2014 Dec 27.

7.

Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL.

Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18.

8.

Genomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosus.

Singh N, Traisak P, Martin KA, Kaplan MJ, Cohen PL, Denny MF.

Arthritis Res Ther. 2014 Aug 8;16(4):R165. doi: 10.1186/ar4681.

9.

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.

Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, Miller CA, Niu B, McLellan MD, Dees ND, Fulton R, Elliot K, Heath S, Grillot M, Westervelt P, Link DC, DiPersio JF, Mardis E, Ley TJ, Wilson RK, Graubert TA.

Leukemia. 2013 Jun;27(6):1275-82. doi: 10.1038/leu.2013.58. Epub 2013 Feb 27.

10.

Molecular pathophysiology of myelodysplastic syndromes.

Lindsley RC, Ebert BL.

Annu Rev Pathol. 2013 Jan 24;8:21-47. doi: 10.1146/annurev-pathol-011811-132436. Epub 2012 Aug 28. Review.

11.

Clonal architecture of secondary acute myeloid leukemia.

Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, Larson DE, McLellan MD, Dooling D, Abbott R, Fulton R, Magrini V, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Fan X, Grillot M, Witowski S, Heath S, Frater JL, Eades W, Tomasson M, Westervelt P, DiPersio JF, Link DC, Mardis ER, Ley TJ, Wilson RK, Graubert TA.

N Engl J Med. 2012 Mar 22;366(12):1090-8. doi: 10.1056/NEJMoa1106968. Epub 2012 Mar 14.

12.

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.

Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, Koboldt DC, Larson DE, McLellan MD, Dooling DJ, Abbott RM, Fulton RS, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Grillot M, Baty J, Heath S, Frater JL, Nasim T, Link DC, Tomasson MH, Westervelt P, DiPersio JF, Mardis ER, Ley TJ, Wilson RK, Walter MJ.

Nat Genet. 2011 Dec 11;44(1):53-7. doi: 10.1038/ng.1031.

13.

Myelodysplastic syndromes.

Odenike O, Anastasi J, Le Beau MM.

Clin Lab Med. 2011 Dec;31(4):763-84. doi: 10.1016/j.cll.2011.08.005. Epub 2011 Oct 10. Review.

14.

Genetic pathways leading to therapy-related myeloid neoplasms.

Stoddart A, McNerney ME, Bartom E, Bergerson R, Young DJ, Qian Z, Wang J, Fernald AA, Davis EM, Larson RA, White KP, Le Beau MM.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011019. doi: 10.4084/MJHID.2011.019. Epub 2011 May 16.

15.

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.

Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Kandoth C, Baty J, Westervelt P, DiPersio JF, Mardis ER, Wilson RK, Ley TJ, Graubert TA.

Leukemia. 2011 Jul;25(7):1153-8. doi: 10.1038/leu.2011.44. Epub 2011 Mar 18.

16.

Treatment-related myelodysplastic syndrome: molecular characteristics and therapy.

Bhatia R, Deeg HJ.

Curr Opin Hematol. 2011 Mar;18(2):77-82. doi: 10.1097/MOH.0b013e328343997a. Review.

17.

Evidence-based genomic diagnosis characterized chromosomal and cryptic imbalances in 30 elderly patients with myelodysplastic syndrome and acute myeloid leukemia.

Bajaj R, Xu F, Xiang B, Wilcox K, Diadamo AJ, Kumar R, Pietraszkiewicz A, Halene S, Li P.

Mol Cytogenet. 2011 Jan 20;4:3. doi: 10.1186/1755-8166-4-3.

18.

Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Bejar R, Levine R, Ebert BL.

J Clin Oncol. 2011 Feb 10;29(5):504-15. doi: 10.1200/JCO.2010.31.1175. Epub 2011 Jan 10. Review.

19.

Genetic deletions in AML and MDS.

Ebert BL.

Best Pract Res Clin Haematol. 2010 Dec;23(4):457-61. doi: 10.1016/j.beha.2010.09.006. Epub 2010 Nov 4. Review.

20.

Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.

Chen TH, Kambal A, Krysiak K, Walshauser MA, Raju G, Tibbitts JF, Walter MJ.

Blood. 2011 Feb 3;117(5):1530-9. doi: 10.1182/blood-2010-06-293167. Epub 2010 Dec 1.

Supplemental Content

Support Center